SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SLS
SELLAS Life Sciences Group, Inc. (SLS) EV/Sales
As of 16 October 2026, SELLAS Life Sciences Group, Inc. (SLS) trades at a EV/Sales of 167×. Over the past ten years it has ranged from 0.0× (December 2020) to 265× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 3.1× | (43.34%) |
| FY2021 | 5.5× | 250.42% |
| FY2020 | 1.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2022 | 8.8× | (25.93%) |
| Jun 2021 | 11.9× | 38.32% |
| Mar 2021 | 8.6× | 448.08% |
| Dec 2020 | 1.6× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| ADMA ADMA Biologics Inc compare | 4.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 23.7× |
| SLS SELLAS Life Sciences Group, Inc. | 167× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)